c-RET
Os inibidores de c-RET têm como alvo o proto-oncogene RET (Rearranged during Transfection), que codifica uma tirosina quinase receptora envolvida no crescimento, diferenciação e sobrevivência celular. A ativação anormal da sinalização RET pode levar à proliferação celular descontrolada e à resistência à apoptose, contribuindo para o desenvolvimento de cânceres como o carcinoma medular da tireoide e o câncer de pulmão de células não pequenas. A inibição de c-RET pode induzir apoptose em células cancerígenas e é uma abordagem promissora na terapia oncológica direcionada. Na CymitQuimica, oferecemos uma variedade de inibidores de c-RET de alta qualidade para apoiar sua pesquisa em oncologia, transdução de sinais e apoptose.
Foram encontrados 60 produtos de "c-RET"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS:BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Fórmula:C23H27F4N3O4SPureza:99.23%Cor e Forma:SolidPeso molecular:517.54Ref: TM-T10624
1mg43,00€2mg57,00€5mg96,00€10mg134,00€25mg220,00€50mg329,00€100mg470,00€1mL*10mM (DMSO)97,00€QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Fórmula:C53H54N12O4Cor e Forma:SolidPeso molecular:923.07RET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. It demonstrates inhibitory effects on BaF3 cells with the CCDC6-RETV804M mutation, with an IC50 of 0.715 μM. RET-IN-29 shows potential for research in non-small cell lung cancer (NSCLC).Fórmula:C22H22N6OCor e Forma:SolidPeso molecular:386.45RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Fórmula:C38H42N10O3Cor e Forma:SolidPeso molecular:686.81YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Fórmula:C58H63F3N12O9Cor e Forma:SolidPeso molecular:1129.19AD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Fórmula:C22H21ClF3N7OPureza:98%Cor e Forma:SolidPeso molecular:491.9RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Cor e Forma:Odour SolidCDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Fórmula:C29H26N4OPeso molecular:446.21066Compound TPX-0046
CAS:Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Fórmula:C21H21FN6O3Pureza:99.94%Cor e Forma:SoildPeso molecular:424.43PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Fórmula:C22H22FN5O2Cor e Forma:SolidPeso molecular:407.44RET-IN-28
CAS:RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.Fórmula:C26H29N9Cor e Forma:SolidPeso molecular:467.57RET-IN-4
CAS:RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Fórmula:C27H31FN10O2Cor e Forma:SolidPeso molecular:546.611BT44
CAS:BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Fórmula:C28H27F4N3O4SPureza:99.87%Cor e Forma:SoildPeso molecular:577.59Ref: TM-T67733
1mg74,00€5mg160,00€10mg235,00€25mg424,00€50mg635,00€100mg924,00€1mL*10mM (DMSO)188,00€RET ligand-1
CAS:RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Fórmula:C28H24F2N6O3Cor e Forma:SolidPeso molecular:530.525Zeteletinib hemiadipate
CAS:Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Fórmula:C56H56F6N8O12Cor e Forma:SolidPeso molecular:1147.098RET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Fórmula:C40H44N10OCor e Forma:SolidPeso molecular:680.84trans-Pralsetinib
CAS:trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).Fórmula:C27H32FN9O2Pureza:98%Cor e Forma:SolidPeso molecular:533.6Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFórmula:C27H32FN9O2Pureza:97.88% - 99.8%Cor e Forma:SolidPeso molecular:533.6BBT594
CAS:BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.Fórmula:C28H30F3N7O3Pureza:99.57%Cor e Forma:SolidPeso molecular:569.58RET V804M-IN-1
CAS:RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).Fórmula:C19H16N6OPureza:97.94% - 99.62%Cor e Forma:SolidPeso molecular:344.37Ref: TM-T8467
1mg35,00€2mg50,00€5mg74,00€10mg90,00€25mg157,00€50mg236,00€100mg334,00€200mg495,00€1mL*10mM (DMSO)82,00€TPX-0046
CAS:TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
Fórmula:C21H21FN6O3Pureza:99.95%Cor e Forma:SolidPeso molecular:424.43Selpercatinib
CAS:"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."Fórmula:C29H31N7O3Pureza:99.89% - >99.99%Cor e Forma:SolidPeso molecular:525.6Ref: TM-T8222
2mg34,00€5mg49,00€10mg84,00€25mg166,00€50mg259,00€100mg477,00€200mg692,00€500mg1.035,00€1mL*10mM (DMSO)56,00€Pyrazoloadenine
CAS:Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.Fórmula:C5H5N5Pureza:99.02%Cor e Forma:Beige PowderPeso molecular:135.13GSK3179106
CAS:GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nMFórmula:C22H21F4N3O4Pureza:99.8% - 99.90%Cor e Forma:SolidPeso molecular:467.41Treprostinil Sodium
CAS:Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).Fórmula:C23H33NaO5Pureza:99.67% - >99.99%Cor e Forma:SolidPeso molecular:412.5SPP-86
CAS:SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Fórmula:C16H15N5Pureza:99.53%Cor e Forma:SolidPeso molecular:277.32Ref: TM-T16923
1mg46,00€5mg90,00€10mg144,00€25mg281,00€50mg447,00€100mg650,00€500mg1.369,00€1mL*10mM (DMSO)90,00€AD80
CAS:AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.Fórmula:C22H19F4N7OPureza:99.49% - 99.75%Cor e Forma:SolidPeso molecular:473.43Ref: TM-T4301
1mg44,00€5mg96,00€10mg138,00€25mg268,00€50mg439,00€100mg645,00€500mg1.333,00€1mL*10mM (DMSO)90,00€WHI-P180 hydrochloride
CAS:WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.Fórmula:C16H16ClN3O3Cor e Forma:SolidPeso molecular:333.77WHI-P180
CAS:WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Fórmula:C16H15N3O3Pureza:99.21%Cor e Forma:SolidPeso molecular:297.31TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Fórmula:C29H31F3N8OPureza:98%Cor e Forma:SolidPeso molecular:564.6RET-IN-16
CAS:RET-IN-16: Selective RET inhibitor, IC50s 3.98-15.05 nM for various RET mutations; anticancer properties.Fórmula:C31H29F3N8O2Cor e Forma:SolidPeso molecular:602.61RET-IN-22
CAS:RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-Fórmula:C29H31F3N6O4Cor e Forma:SolidPeso molecular:584.59RET-IN-8
CAS:RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Fórmula:C27H30N6O3Cor e Forma:SolidPeso molecular:486.57RET-IN-6
CAS:RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).Fórmula:C30H29N7Cor e Forma:SolidPeso molecular:487.6XMD15-44
CAS:XMD15-44, a RET kinase inhibitor, demonstrates potent growth-inhibitory effects on RAT1 cells transformed by RET/C634R and RET/M918T, with IC50 values of 11.5 nM and 8.3 nM, respectively. It effectively inhibits RET kinase activity and signaling in human thyroid cancer cell lines harboring oncogenic RET alleles, thereby reducing cell proliferation.Fórmula:C29H29F3N4OCor e Forma:SolidPeso molecular:506.56RET-IN-15
CAS:RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Fórmula:C27H28N8O2Cor e Forma:SolidPeso molecular:496.56RET-IN-12
CAS:RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).Fórmula:C30H30F3N5O4Cor e Forma:SolidPeso molecular:581.59DUN73423
CAS:DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.Fórmula:C19H16N6OPureza:98.09%Cor e Forma:SolidPeso molecular:344.37RET-IN-3
CAS:RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.Fórmula:C18H21N5O2Pureza:99.52%Cor e Forma:SolidPeso molecular:339.39Ref: TM-T9673
1mg73,00€5mg158,00€10mg240,00€25mg452,00€50mg712,00€100mg1.093,00€200mg1.473,00€1mL*10mM (DMSO)168,00€RET-IN-23
CAS:RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.Fórmula:C28H28FN11Pureza:97.46%Cor e Forma:SolidPeso molecular:537.59TG-89
CAS:TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFórmula:C26H34N6O3SPureza:98.68%Cor e Forma:SolidPeso molecular:510.65Pz-1
CAS:Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.Fórmula:C26H26N6O2Pureza:99.89%Cor e Forma:SolidPeso molecular:454.52RET-IN-13
CAS:RET-IN-13: potent quinoline RET inhibitor; IC50 = 0.5 nM (WT), 0.9 nM (V804M); potential for RET-related tumor/intestinal disease research.Fórmula:C32H33F4N5O3Cor e Forma:SolidPeso molecular:611.63NSC194598
CAS:NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.Fórmula:C20H19N3OCor e Forma:SolidPeso molecular:317.38FHND5071
CAS:FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumorFórmula:C30H30D3N9OCor e Forma:SolidPeso molecular:538.66FLT3/ITD-IN-4
CAS:FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Fórmula:C25H22N4O5Cor e Forma:SolidPeso molecular:458.47RET-IN-5
CAS:RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).Fórmula:C29H26FN9OCor e Forma:SolidPeso molecular:535.57RET-IN-24
CAS:RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].Fórmula:C27H26F2N8OCor e Forma:SolidPeso molecular:516.55RET-IN-25
CAS:RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximalFórmula:C22H17N3O5SCor e Forma:SolidPeso molecular:435.45RET-IN-17
CAS:RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.Fórmula:C27H28F4N4O4Cor e Forma:SolidPeso molecular:548.53RET-IN-9
CAS:RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.Fórmula:C26H27N9OCor e Forma:SolidPeso molecular:481.55FHND5071 (1H)
CAS:FHND5071 (1H) is a selective inhibitor of RET (rearranged during transfection) tyrosine kinase. It shows potential for research applications in RET-driven cancers, such as thyroid and lung cancer.Fórmula:C30H33N9OCor e Forma:SolidPeso molecular:535.64LRRK2-IN-17
CAS:LRRK2-IN-17 is an orally active LRRK2 inhibitor with IC50 values of 3.5 nM for WT and 3.3 nM for G2019S, and it also inhibits RET kinase with an IC50 of 59 nM. LRRK2-IN-17 is utilized in research related to cancer and Parkinson's disease (PD).Fórmula:C18H18N8Cor e Forma:SolidPeso molecular:346.39RET-IN-10
CAS:RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).Fórmula:C29H28N8OSCor e Forma:SolidPeso molecular:536.65TAS05567
CAS:TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Fórmula:C21H29N9O2Pureza:98%Cor e Forma:SolidPeso molecular:439.51RET-IN-30
CAS:RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. It is capable of inhibiting the proliferation of A549 cells and demonstrates antitumor properties.Fórmula:C26H26FN5OCor e Forma:SolidPeso molecular:443.52RET-IN-7
CAS:RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice throughFórmula:C22H24ClFN6O2Cor e Forma:SolidPeso molecular:458.92RET-IN-1
CAS:RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).Fórmula:C29H31N9O3Pureza:98%Cor e Forma:SolidPeso molecular:553.61WF-47-JS03
WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.
Fórmula:C30H38N6O2Cor e Forma:SolidPeso molecular:514.66Enbezotinib
CAS:Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.Fórmula:C21H21FN6O3Pureza:99.84%Cor e Forma:SolidPeso molecular:424.43Ref: TM-T62285
1mg77,00€5mg166,00€10mg253,00€25mg414,00€50mg567,00€100mg745,00€1mL*10mM (DMSO)182,00€
